J&J settles Amgen clash over blockbuster psoriasis drug

Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

J&J awarded $18m in fake surgical devices case

27 July 2023 Judge enters default judgment and permanent injunction order after defendant failed to show in court | Alleged counterfeit medical tools were being sold under Ethicon brand.

Big Pharma

J&J hit with suit over Neutrogena products

20 April 2023 Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.

Americas

Eye care company settles with J&J Surgical Vision for $199m

13 February 2023 J&J had accused defendant of infringing patents related to cataract surgery | Company also complained its copyright-protected computer programs had been ripped off, alleging “piracy of a nearly unfathomable scale”.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

J&J settles Amgen clash over blockbuster psoriasis drug

More on this story

Editor's picks

Editor's picks

More features